Lannett receives approval for generic Loxitane
PHILADELPHIA — Lannett has received regulatory approval from the Food and Drug Administration for its version of an antipsychotic treatment.
The drug maker said the FDA approved its abbreviated new drug application for loxapine capsules in the 5-mg, 10-mg, 25-mg and 50-mg strengths. The drug is a generic version of Watson Pharmaceuticals’ Loxitane.
“We have now received five product approvals from the FDA over the last three months,” Lannett president and CEO Arthur Bedrosian said. “Loxapine capsules is an important addition to our product lineup.”
AmerisourceBergen acquires TheraCom from CVS for $250 million
VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.
TheraCom is a provider of commercialization support services to the biotech and pharmaceutical industry, specifically, providing reimbursement and patient access support services, and will join Lash Group as part of AmerisourceBergen Consulting Services.
"The acquisition of TheraCom will significantly increase the size and scope of our consulting services offering and meaningfully expands our reimbursement, adherence and patient access services for pharmaceutical and biotech manufacturers," AmerisourceBergen president and CEO Steven Collis said. "The addition of TheraCom’s capabilities to our market-leading consulting services will provide our manufacturer customers with enhanced solutions to meet the challenges in the changing healthcare landscape, and will help ensure even greater patient access to medication therapies."
Together, Lash Group and TheraCom will offer an extensive platform of services and solutions to support the growing demand for patient access and reimbursement services, and support the need for unique distribution solutions, the company stated.
TheraCom’s annualized revenues are approximately $700 million, the majority of which are provided by the specialized distribution component of the integrated reimbursement support services for certain unique prescription products.
CVS study: Standards vary among diabetes social media sites
WOONSOCKET, R.I. — As consumers and patients increasingly use social media as a healthcare tool and resource, a survey by Harvard University, Brigham and Women’s Hospital, and CVS Caremark researchers found a need to improve site guidelines, as there is great variability in the standards used to ensure a site effectively provides information and answers to important health-related questions.
The researchers examined diabetes-related social media sites and found they all use different communication and financing structures, varying in how they offer expert participation, and have little in common when it comes to oversight of content and membership criteria. The research was published on Monday in the Archives of Internal Medicine.
"Online social networks may play an increasing role in health education as primary care physicians see increasing numbers of patients, limiting time for telephone consultations to answer questions related to chronic disease management, and as a Web-savvy population ages and develops more chronic diseases," the researchers said. "Our evaluation of commonly used online social networks focused on diabetes highlights the popularity and wide variability [of the Internet sites]."
The researchers began their review by identifying 300 online diabetes-related sites identified through a Google search. They narrowed that number to 23 websites that were not attached to any news or academic institutions. The final study reviewed 15 websites in depth, ranging in size from having 3,074 members to more than 300,000, with a majority having more than 10,000 members. Eighty percent of the sites linked to Facebook, while two-thirds networked through Twitter.
The researchers indicated that information required for site membership was minimal and only one site required an extensive profile be sent to the site administrator for approval. Physicians were available to answer questions on only 33% of the sites, while 67% of the sites called for site administrators to review content. The researchers noted that on 13% of the sites there was no apparent policing of information posted.
Industry advertising is allowed on all but three of the sites. Half of the sites that featured advertising had information from pharmaceutical manufacturers, 67% had ads from diabetes device manufacturers, and 13% published ads purchased by insurance companies. In addition, two-thirds of the sites allowed advertisements related to diet and exercise for diabetics.
"We are looking at these sites with a critical eye because they represent an important healthcare tool of the future, and it is essential to determine how they can best help patients treat their chronic disease," said William H. Shrank of Harvard and Brigham and Women’s and lead author of the study. "We were surprised at how differently they operate. There is clearly work ahead to make social media a powerful tool in helping patients manage their chronic illnesses."
"Social media is clearly attractive to people looking to share information and to find support and strategies for living with chronic disease," added Troyen A. Brennan, EVP and chief medical officer of CVS Caremark. "This study shows we have a long way to go before we can be confident patients are receiving high quality, accurate information about their conditions through this medium."